Effective treatment of a patient with stage IV ovarian cancer: A case report

Huang,Zhen; Yan,Hua; Chavan,Devendra; Yuan,Zeng; Yang,Xingsheng; Zhang,Youzhong; Song,Kun; Kong,Beihua

doi:10.3892/ol.2017.7285

Effective treatment of a patient with stage IV ovarian cancer: A case report

Authors:
- Zhen Huang
- Hua Yan
- Devendra Chavan
- Zeng Yuan
- Xingsheng Yang
- Youzhong Zhang
- Kun Song
- Beihua Kong
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Spleen and Stomach Diseases, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250012, P.R. China
Published online on: October 30, 2017 https://doi.org/10.3892/ol.2017.7285
Pages: 588-591

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present case report describes a patient with stage IV ovarian cancer who survived for 9 years without achieving a complete remission since the first relapse. The patient's long‑term survival may be ascribed to the slow growth of the cancer cells, limited metastasis and favorable responses to the treatments received. The patient manifested initially with malignant pleural effusion and was not able to tolerate surgical treatment. However, the disease was well‑controlled using various treatments, including neoadjuvant chemotherapy, interval cytoreductive surgery and post‑operative long‑term chemotherapy. Management of ovarian cancer is most effective when tailored to the individual needs of the patient, maximizing its efficacy and prolonging the patient's survival rate. The present case may offer useful insight into the clinical management of stage IV ovarian cancer

View Figures

View References

1	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
2	Narod S: Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 13:255–261. 2016. View Article : Google Scholar : PubMed/NCBI
3	Davidson B and Tropé CG: Ovarian cancer: Diagnostic, biological and prognostic aspects. Womens Health (Lond). 10:519–533. 2014. View Article : Google Scholar : PubMed/NCBI
4	van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J and Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med. 332:629–634. 1995. View Article : Google Scholar : PubMed/NCBI
5	Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG and Blackledge GR: Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol. 101:142–146. 1994. View Article : Google Scholar : PubMed/NCBI
6	Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH and Small JM; Gynecologic Oncology Group, : Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 351:2489–2497. 2004. View Article : Google Scholar : PubMed/NCBI
7	Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010. View Article : Google Scholar : PubMed/NCBI
8	Colombo N: Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: New data from the randomized OVA-301 study. Int J Gynecol Cancer. 21 Suppl 1:S12–S16. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, et al: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol. 22:49–58. 2011. View Article : Google Scholar : PubMed/NCBI
10	Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, et al: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: Outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 22:39–48. 2011. View Article : Google Scholar : PubMed/NCBI
11	Rustin GJ: Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 22 Suppl 8:viii45–viii48. 2011. View Article : Google Scholar : PubMed/NCBI